Advertisement
Legal/Regulatory
Subscribe to Legal/Regulatory

The Lead

Amgen Terminates Co-Development of Brodalumab with AstraZeneca

May 26, 2015 1:16 pm | by Stephanie Guzowski, Editor | News | Comments

Amgen ended its co-development of brodalumab with AstraZeneca after some patients who took the experimental psoriasis drug experienced suicidal thoughts or behavior, which Amgen believes would likely require restrictive labeling. Read more...

Countries Approve Plan for $100M Emergency Health Fund

May 26, 2015 7:56 am | by The Associated Press | News | Comments

Diplomats have approved the creation of a $100 million fund to help the World Health...

Emmes Announces FDA Clearance of New Medical Device

May 21, 2015 1:18 pm | News | Comments

The Emmes Corporation today announced that the U.S. Food and Drug Administration (FDA) has given...

FDA Proposes to Know More About Antibiotic Use in Animals

May 21, 2015 9:51 am | by Mary Clare Jalonick, Associated Press | News | Comments

The Food and Drug Administration is moving to collect more information on antibiotics used in...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Activists Want to Void Patents on Gilead's High-Priced Hepatitis C Drug

May 20, 2015 12:15 pm | by Ryan Bushey, Associate Editor | Articles | Comments

These patents are being challenged all over the world. Read more...

HIV Reservoirs Remain Obstacles to Cure

May 20, 2015 8:41 am | by NIAID | News | Comments

A primary research goal is to find an HIV cure that either clears the virus from an infected person’s body or enables HIV-infected individuals to suppress virus levels and replication to extremely low levels without the need for daily ART. Read more...

HedgePath Pharmaceuticals To Receive $2.5 Million in Funding From Mayne Pharma

May 19, 2015 12:36 pm | News | Comments

HedgePath Pharmaceuticals, Inc., a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it has entered into a definitive agreement with an affiliate of Mayne Pharma Group Limited under which Mayne Pharma will invest $2.5 million in HPPI in a private common stock and warrant financing.  Read more...

Advertisement

Global Dyslipidemia Treatment Market Value Will Approach $38B by 2023

May 19, 2015 8:44 am | by Valentina Gburcik, Ph.D., Director of Cardiovascular & Metabolic Disorders, GlobalData | Articles | Comments

The global treatment market for dyslipidemia will more than double in value from $15.4 billion in 2013 to an estimated $37.9 billion by 2023. Read more...

AbbVie Receives Orphan Drug Designation for Humira

May 18, 2015 11:27 am | News | Comments

AbbVie announced that the U.S. Food and Drug Administration (FDA) has granted HUMIRA® (adalimumab) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hurley Stage III disease), a painful, chronic inflammatory skin disease. Read more...

Specialty Drugs Spotlight: The Week’s Top Pharma News

May 15, 2015 2:25 pm | by Stephanie Guzowski, Editor | News | Comments

From pharma collaborations on therapies to fallouts over failed clinical trials, here are your headlines this week. Read more...

ANI Pharmaceuticals Acquires Rights to Testosterone Gel 1%

May 14, 2015 12:50 pm | News | Comments

ANI Pharmaceuticals, Inc. today announced that it has acquired the approved new drug application ("NDA") for a testosterone gel 1% product previously licensed to Teva Pharmaceuticals. Read more...

Early Data Release Ends Obesity Drug Study

May 13, 2015 12:50 pm | by Stephanie Guzowski, Editor | News | Comments

A safety study of obesity drug Contrave has been terminated after Orexigen Therapeutics released early, misleading trial data, say researchers. Takeda Pharmaceutical is seeking to end its collaboration with Orexigen. Read more...

Advertisement

Orexigen: Statement on Termination of Study, Updates on Contrave Collaboration with Takeda

May 13, 2015 12:39 pm | News | Comments

Orexigen Therapeutics, Inc. Tuesday issued the following statement regarding the termination of the Light Study a cardiovascular (CV) outcomes trial that compared the obesity drug Contrave. Read more...

FDA Panel Backs Vertex Combination Pill for Cystic Fibrosis

May 13, 2015 10:11 am | by Matthew Perrone, AP Health Writer - Associated Press | News | Comments

Federal health advisers on Tuesday recommended approval for an experimental combination drug to treat cystic fibrosis, despite unresolved questions about the benefit of one of the pill's two ingredients. Read more...

Eli Lilly and German Startup Collaborating on Cancer Immunotherapies

May 12, 2015 12:23 pm | by Seth Augenstein, Digital Reporter | News | Comments

Pharma giant Eli Lilly and Company and a German startup have reached a highly-incentivized agreement to collaborate on new cancer treatments arming the body’s immune system to fight tumors, the companies announced. Read more...

Imprimis Pharmaceuticals : $15M Loan Agreement with Life Sciences Alternative Funding

May 12, 2015 10:55 am | News | Comments

Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced it has entered into a loan agreement with IMMY Funding LLC, an affiliate of Life Sciences Alternative Funding LLC (LSAF), a leading provider of debt capital to fund growth for commercial-stage life sciences companies. Read more...

The Michael J. Fox Foundation, Imago Pharmaceuticals Partner to Speed Parkinson's Research

May 12, 2015 10:50 am | News | Comments

The Michael J. Fox Foundation for Parkinson's Research (MJFF) announces the acquisition of a library of research tools around the parkin protein from Imago Pharmaceuticals. Read more...

Advertisement

The U.S. Looks to Improve on Cuba's Lung Cancer Vaccine

May 12, 2015 8:38 am | by Ryan Bushey, Associate Editor | Articles | Comments

The injection is being evaluated as a possible preventative intervention. Read more...

FDA Questions Benefit of Cystic Fibrosis Drug From Vertex

May 11, 2015 10:47 am | by Matthew Perrone, AP Health Writer | News | Comments

Federal health regulators have questions about the benefits of an experimental combination drug for cystic fibrosis, including whether the addition of a second drug ingredient adds to the pill's effectiveness. Read more...

2 Babies Die, 29 Sickened from Bad Vaccines in South Mexico

May 11, 2015 9:31 am | by The Associated Press | News | Comments

Mexico's public health system has suspended infant vaccines and mounted an investigation after two babies died and 29 were sickened in an impoverished community in southern Mexico. Read more...

Debiotech Gets Exclusive Option Rights for iSense Patch Pumps

May 11, 2015 9:19 am | News | Comments

These tools will be used for diabetes therapy. Read more...

California Court Sides with Consumers in Generic Drug Fight

May 8, 2015 11:06 am | by Sudhin Thanawala, Associated Press | News | Comments

In a win for consumers, the California Supreme Court ruled Thursday that settlement agreements between pharmaceutical companies that keep cheaper, generic drugs off the market may be illegal if they include excessive cash payments. Read more...

FDA Schedules Meeting on Twice-Rejected Female Libido Drug

May 8, 2015 10:57 am | by Matthew Perrone, AP Health Writer | News | Comments

The Food and Drug Administration will ask a group of outside medical experts next month to evaluate a much-debated experimental drug designed to boost sexual desire in women. Read more...

AbbVie Receives Breakthrough Designation for Cancer Drug

May 7, 2015 11:40 am | by Stephanie Guzowski, Editor | News | Comments

The U.S. Food and Drug Administration has granted breakthrough therapy designation for its leukemia drug, venetoclax, to speed up the regulatory review process. Read more...

J&J Seeks Bioethics Advice on Compassionate Use of Drugs

May 7, 2015 10:27 am | by Lauren Neergaard, AP Medical Writer - Associated Press | News | Comments

Dying patients sometimes seek emergency access to experimental medicines, desperate for a last-chance treatment even if there's little proof it could help. Now drug giant Johnson & Johnson is taking an unusual step, turning to independent bioethicists for advice on when to say yes or no. Read more...

Silver Creek Awarded NIH Grant for Smart Growth Factor Technology

May 6, 2015 9:46 am | News | Comments

Silver Creek Pharmaceuticals, Inc. announced today the award of a Small Business Innovation Research (SBIR) grant from the National Institute of Health (NIH). Proceeds from the award will be used to advance novel "Smart Growth Factors" toward clinical development. Read more...

Aetna Curtails Coverage of Surgical Tool Tied to Cancer Risk

May 6, 2015 9:35 am | by Associated Press | News | Comments

The health insurer Aetna is ending most coverage of hysterectomies performed with a once-popular device that has drawn warnings from federal regulators over a risk for spreading cancer. Read more..

Bayer Licenses ISIS FXIRx from Isis Pharmaceuticals

May 5, 2015 11:33 am | News | Comments

Bayer HealthCare (Bayer) has entered into an exclusive license agreement with Isis Pharmaceuticals, Inc. on ISIS-FXIRx, an antisense investigational drug in clinical development for the prevention of thrombosis. Read more...

China to Lift Price Controls on Most Drugs Starting June 1st

May 5, 2015 8:35 am | by The Associated Press | News | Comments

Chinese regulators will lift price controls on most pharmaceutical drugs starting June 1 in hopes that the market-driven pricing system will keep medical costs in check. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading